Exelixis Inc at Barclays Global Healthcare Conference Transcript
Good afternoon. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. It's my great pleasure to introduce Mike Morrissey, CEO of Exelixis. And also, we have Chris Senner, CFO from Exelixis.
Maybe, Mike, just as a general introductory question before we get into the major -- main Q&A section, perhaps you could give us a high-level overview of the company, when your lead drug was approved and indications you target. Thank you.
Yes, absolutely. Good afternoon, everybody. This is Mike Morrissey. Before I begin today, I'll remind you that I'll be making forward-looking statements today, so please see our SEC filings for a risk -- for a description of the risks that we face in our business.
So Exelixis, commercial stage biotech company focused in the area of oncology. Our main drug is CABOMETYX, generic name is cabozantinib, which is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
